GlycoMimetics Inc. (GLYC) NASDAQ
$1.41 0.02 (1.44%)
Market Cap: $72.87M
As of 03/27/23 04:00 PM EDT. Market closed.
GlycoMimetics Inc. (GLYC)
NASDAQ
$1.41
0.02 (1.44%)
Market Cap: $72.87M
As of 03/27/23 04:00 PM EDT. Market closed.
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being ... read more
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has an ongoing Phase 1b clinical trial evaluating GMI-1359, a combined CXCR4 and E-selectin antagonist, also a wholly-owned drug candidate. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Rachel King
Full Time Employees
52
CEO Compensation (Base)
$543,000
CEO Compensation (Total)
$3.19M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Rachel King
Full Time Employees
52
CEO Compensation (Base)
$543,000
CEO Compensation (Total)
$3.19M
Address
9708 Medical Center Dr, Maryland, Rockville, 20850-3343.
PRICE CHART FOR GLYCOMIMETICS INC
From:
To:
NEWS
KEY STATS
Open
$1.41
Previous Close
$1.39
Days Range
$1.36 - $1.44
52 week range
$0.51 - $4.16
Volume
211,039
Avg. Volume (30 days)
647,651
Market Cap
$72.87M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
52,423,944
Open
$1.41
Previous Close
$1.39
Days Range
$1.36 - $1.44
52 week range
$0.51 - $4.16
Volume
211,039
Avg. Volume (30 days)
647,651
Market Cap
$72.87M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
52,423,944
Open in: 
Open in:
INSIDER TRANSACTIONS FOR GLYCOMIMETICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Invus Public Equities, L.P. | 10% Owner | Feb 24, 2023 | Buy | $1.70 | 100,000 | 170,000 | 8,589,064 | Feb 28, 2023, 05:33 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 23, 2023 | Buy | $1.75 | 200,000 | 350,760 | 8,489,064 | Feb 23, 2023, 06:23 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 22, 2023 | Buy | $1.79 | 150,000 | 268,995 | 8,289,064 | Feb 23, 2023, 06:23 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 21, 2023 | Buy | $1.85 | 50,000 | 92,500 | 8,139,064 | Feb 23, 2023, 06:23 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 16, 2023 | Buy | $1.68 | 315,266 | 531,129 | 7,889,064 | Feb 17, 2023, 05:29 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 15, 2023 | Buy | $2.16 | 1,000,000 | 2,155,800 | 7,573,798 | Feb 17, 2023, 05:29 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 17, 2023 | Buy | $1.71 | 200,000 | 341,000 | 8,089,064 | Feb 17, 2023, 05:29 PM |
| Invus Public Equities, L.P. | 10% Owner | Feb 09, 2023 | Buy | $3.24 | 11,451 | 37,123 | 6,573,798 | Feb 13, 2023, 05:45 PM |
| Koenig Scott | Director | Jan 27, 2023 | Option Exercise | $2.55 | 10,500 | 26,775 | 15,750 | Jan 30, 2023, 04:13 PM |
| SANDELL SCOTT D | 10% Owner | Jan 25, 2023 | Sale | $3.26 | 293,645 | 958,428 | 3,588,288 | Jan 27, 2023, 05:15 PM |
| SANDELL SCOTT D | 10% Owner | Jan 25, 2023 | Sale | $3.26 | 358,371 | 1,169,687 | 4,379,242 | Jan 27, 2023, 05:15 PM |
| SANDELL SCOTT D | 10% Owner | Jan 26, 2023 | Sale | $3.12 | 1,351,092 | 4,213,786 | 2,237,196 | Jan 27, 2023, 05:15 PM |
| SANDELL SCOTT D | 10% Owner | Jan 26, 2023 | Sale | $3.12 | 1,648,908 | 5,142,614 | 2,730,334 | Jan 27, 2023, 05:15 PM |
| SANDELL SCOTT D | 10% Owner | Jan 05, 2023 | Sale | $2.76 | 32,139 | 88,659 | 3,881,933 | Jan 06, 2023, 06:35 PM |
| SANDELL SCOTT D | 10% Owner | Jan 05, 2023 | Sale | $2.76 | 39,223 | 108,201 | 4,737,613 | Jan 06, 2023, 06:35 PM |
| SANDELL SCOTT D | 10% Owner | Jan 03, 2023 | Sale | $2.99 | 96,084 | 287,301 | 4,832,890 | Jan 04, 2023, 05:26 PM |
| SANDELL SCOTT D | 10% Owner | Dec 30, 2022 | Sale | $3.02 | 54,645 | 165,028 | 4,038,732 | Jan 04, 2023, 05:26 PM |
| SANDELL SCOTT D | 10% Owner | Dec 30, 2022 | Sale | $3.02 | 66,690 | 201,404 | 4,928,974 | Jan 04, 2023, 05:26 PM |
| SANDELL SCOTT D | 10% Owner | Jan 04, 2023 | Sale | $2.91 | 45,930 | 133,643 | 3,914,072 | Jan 04, 2023, 05:26 PM |
| SANDELL SCOTT D | 10% Owner | Jan 04, 2023 | Sale | $2.91 | 56,054 | 163,100 | 4,776,836 | Jan 04, 2023, 05:26 PM |
| SANDELL SCOTT D | 10% Owner | Jan 03, 2023 | Sale | $2.99 | 78,730 | 235,411 | 3,960,002 | Jan 04, 2023, 05:26 PM |
| Rock Edwin | Chief Medical Officer | Dec 22, 2022 | Buy | $2.25 | 110,000 | 247,500 | 310,000 | Dec 27, 2022, 06:41 PM |
| JUNIUS DANIEL M | Director | Nov 17, 2022 | Buy | $1.87 | 20,000 | 37,400 | 63,250 | Nov 18, 2022, 04:01 PM |
| Rock Edwin | Chief Medical Officer | Nov 14, 2022 | Buy | $1.43 | 100,000 | 143,000 | 100,000 | Nov 16, 2022, 04:26 PM |
| Rock Edwin | Chief Medical Officer | Nov 15, 2022 | Buy | $1.66 | 100,000 | 166,000 | 200,000 | Nov 16, 2022, 04:26 PM |
| PEARSON TIMOTHY R | Director | Nov 11, 2022 | Buy | $1.29 | 19,400 | 25,026 | 24,650 | Nov 14, 2022, 04:14 PM |
| Semerjian Harout | Chief Executive Officer | Nov 11, 2022 | Buy | $1.29 | 25,000 | 32,250 | 25,000 | Nov 14, 2022, 04:13 PM |
| Hahn Brian M. | SVP Finance, CFO | Nov 11, 2022 | Buy | $1.06 | 20,000 | 21,200 | 56,843 | Nov 14, 2022, 04:13 PM |
| Magnani John L. | SVP of Research, CSO | Nov 11, 2022 | Buy | $1.17 | 45,045 | 52,703 | 366,078 | Nov 14, 2022, 04:11 PM |
| Girard Armand | SVP, Chief Business Officer | Nov 11, 2022 | Buy | $1.05 | 6,500 | 6,825 | 29,161 | Nov 14, 2022, 04:04 PM |
| Magnani John L. | SVP of Research, CSO | Mar 09, 2022 | Sale | $1.09 | 3,227 | 3,517 | 321,033 | Mar 10, 2022, 05:06 PM |
| Girard Armand | SVP, Chief Business Officer | Mar 09, 2022 | Sale | $1.09 | 2,339 | 2,550 | 22,661 | Mar 10, 2022, 05:05 PM |
| Hahn Brian M. | SVP Finance, CFO | Mar 09, 2022 | Sale | $1.09 | 2,917 | 3,180 | 36,843 | Mar 10, 2022, 05:03 PM |
| Andrews Patricia S | Director | Nov 16, 2021 | Buy | $2.05 | 40,000 | 82,000 | 45,250 | Nov 18, 2021, 04:05 PM |
| King Rachel K. | President, CEO | Dec 28, 2020 | Option Exercise | $1.12 | 130,821 | 146,520 | 440,240 | Dec 30, 2020, 04:00 PM |
| King Rachel K. | President, CEO | Dec 28, 2020 | Sale | $3.91 | 84,176 | 329,128 | 356,064 | Dec 30, 2020, 04:00 PM |
| Hahn Brian M. | SVP Finance, CFO | Dec 16, 2020 | Option Exercise | $1.12 | 5,260 | 5,891 | 5,260 | Dec 17, 2020, 04:00 PM |
| BVF PARTNERS L P/IL | 10% Owner | Nov 04, 2020 | Buy | $2.60 | 1,266,737 | 3,293,516 | 4,980,812 | Nov 06, 2020, 06:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Oct 30, 2020 | Buy | $2.75 | 932,612 | 2,564,683 | 4,306,320 | Nov 03, 2020, 04:44 PM |
| JUNIUS DANIEL M | Director | Mar 09, 2020 | Buy | $3.40 | 20,000 | 68,000 | 38,000 | Mar 10, 2020, 06:12 PM |
| Magnani John L. | SVP of Research, CSO | Jan 06, 2020 | Option Exercise | $1.12 | 106,983 | 119,821 | 289,760 | Jan 06, 2020, 06:23 PM |
| Magnani John L. | SVP of Research, CSO | Dec 20, 2019 | Option Exercise | $1.12 | 106,984 | 119,822 | 182,777 | Dec 23, 2019, 04:13 PM |
| BVF PARTNERS L P/IL | 10% Owner | Sep 05, 2019 | Buy | $3.18 | 1,668,746 | 5,309,950 | 3,639,935 | Sep 09, 2019, 04:49 PM |
| JUNIUS DANIEL M | Director | Aug 13, 2019 | Buy | $3.18 | 10,000 | 31,800 | 18,000 | Aug 15, 2019, 04:03 PM |
| King Rachel K. | President, CEO | Aug 06, 2019 | Option Exercise | $1.12 | 166,759 | 186,770 | 307,144 | Aug 07, 2019, 04:29 PM |
| Magnani John L. | SVP of Research, CSO | Oct 18, 2018 | Sale | $14.02 | 3,527 | 49,449 | 75,793 | Oct 18, 2018, 05:36 PM |
| Magnani John L. | SVP of Research, CSO | Oct 17, 2018 | Sale | $14.00 | 7,273 | 101,822 | 79,320 | Oct 18, 2018, 05:36 PM |
| Magnani John L. | SVP of Research, CSO | Oct 16, 2018 | Sale | $14.01 | 14,200 | 198,942 | 86,593 | Oct 18, 2018, 05:36 PM |
| Hahn Brian M. | CFO | Jun 11, 2018 | Option Exercise | $1.12 | 5,260 | 5,891 | 19,345 | Jun 12, 2018, 05:54 PM |
| Hahn Brian M. | CFO | Jun 11, 2018 | Sale | $18.04 | 19,345 | 348,984 | 0 | Jun 12, 2018, 05:54 PM |
| Magnani John L. | SVP of Research, CSO | May 23, 2018 | Option Exercise | $0.33 | 1,491 | 492 | 100,793 | May 24, 2018, 05:11 PM |
| SANDELL SCOTT D | 10% Owner | May 10, 2018 | Sale | $17.81 | 9,539 | 169,890 | 4,995,664 | May 11, 2018, 05:02 PM |
| SANDELL SCOTT D | 10% Owner | May 10, 2018 | Option Exercise | $0.33 | 514,452 | 169,769 | 5,001,197 | May 11, 2018, 05:02 PM |
| BARRIS PETER J | 10% Owner | May 10, 2018 | Sale | $17.81 | 9,539 | 169,890 | 4,995,664 | May 11, 2018, 05:01 PM |
| BARRIS PETER J | 10% Owner | May 10, 2018 | Option Exercise | $0.33 | 514,452 | 169,769 | 5,001,197 | May 11, 2018, 05:01 PM |
| BARRETT M JAMES | Director | May 10, 2018 | Sale | $17.81 | 9,539 | 169,890 | 4,995,664 | May 11, 2018, 05:00 PM |
| BARRETT M JAMES | Director | May 10, 2018 | Option Exercise | $0.33 | 514,452 | 169,769 | 5,001,197 | May 11, 2018, 05:00 PM |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | May 10, 2018 | Sale | $17.81 | 9,539 | 169,890 | 4,995,664 | May 11, 2018, 05:00 PM |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | May 10, 2018 | Option Exercise | $0.33 | 514,452 | 169,769 | 5,001,197 | May 11, 2018, 05:00 PM |
| Thackray Helen M. | SVP Clinical Development, CMO | Dec 08, 2017 | Sale | $15.01 | 2,000 | 30,020 | 148,615 | Dec 12, 2017, 04:14 PM |
| Thackray Helen M. | SVP Clinical Development, CMO | Sep 18, 2017 | Sale | $13.00 | 2,000 | 26,000 | 150,615 | Sep 18, 2017, 06:15 PM |
| JUNIUS DANIEL M | Director | Jun 15, 2017 | Option Exercise | $11.27 | 3,000 | 33,810 | 8,000 | Jun 16, 2017, 05:14 PM |
| Thackray Helen M. | SVP Clinical Development, CMO | May 25, 2017 | Sale | $15.57 | 2,000 | 31,140 | 152,615 | May 30, 2017, 04:07 PM |
| Thackray Helen M. | SVP Clinical Development, CMO | May 19, 2017 | Sale | $12.14 | 2,000 | 24,280 | 154,615 | May 22, 2017, 09:23 PM |
| Magnani John L. | SVP of Research, CSO | May 10, 2017 | Option Exercise | $1.12 | 8,928 | 9,999 | 99,302 | May 11, 2017, 04:00 PM |
| JUNIUS DANIEL M | Director | Dec 20, 2016 | Buy | $6.01 | 5,000 | 30,050 | 5,000 | Dec 21, 2016, 04:23 PM |
| Thackray Helen M. | VP Clinical Development, CMO | Oct 03, 2016 | Sale | $7.00 | 4,000 | 28,001 | 156,715 | Oct 04, 2016, 04:22 PM |
| Thackray Helen M. | VP Clinical Development, CMO | Jul 20, 2016 | Sale | $8.00 | 2,000 | 16,000 | 160,615 | Jul 21, 2016, 05:27 PM |
| Thackray Helen M. | VP Clinical Development, CMO | Jul 05, 2016 | Sale | $7.01 | 10,136 | 71,053 | 169,411 | Jul 06, 2016, 05:07 PM |
| Thackray Helen M. | VP Clinical Development, CMO | Jul 01, 2016 | Sale | $7.40 | 5,068 | 37,503 | 179,547 | Jul 06, 2016, 05:07 PM |
| Thackray Helen M. | VP Clinical Development, CMO | Jul 06, 2016 | Sale | $6.68 | 6,796 | 45,397 | 162,615 | Jul 06, 2016, 05:07 PM |
| Baldwin John J. | Director | Jun 29, 2016 | Option Exercise | $1.12 | 605 | 678 | 1,210 | Jul 01, 2016, 11:43 AM |
| Goldberg Mark Alan | Director | Mar 04, 2016 | Buy | $4.77 | 10,397 | 49,630 | 11,497 | Mar 07, 2016, 08:03 AM |
| TOP FRANKLIN H JR | Director | Feb 05, 2016 | Option Exercise | $1.12 | 11,689 | 13,092 | 12,294 | Feb 12, 2016, 03:30 PM |
| SANDELL SCOTT D | 10% Owner | Nov 16, 2015 | Sale | $6.91 | 452 | 3,123 | 4,490,751 | Nov 18, 2015, 02:20 PM |
| SANDELL SCOTT D | 10% Owner | Nov 16, 2015 | Option Exercise | $0.33 | 9,445 | 3,117 | 4,491,203 | Nov 18, 2015, 02:20 PM |
| BARRIS PETER J | 10% Owner | Nov 16, 2015 | Sale | $6.91 | 452 | 3,123 | 4,490,751 | Nov 18, 2015, 02:20 PM |
| BARRIS PETER J | 10% Owner | Nov 16, 2015 | Option Exercise | $0.33 | 9,445 | 3,117 | 4,491,203 | Nov 18, 2015, 02:20 PM |
| BARRETT M JAMES | Director | Nov 16, 2015 | Sale | $6.91 | 452 | 3,123 | 4,490,751 | Nov 18, 2015, 02:19 PM |
| BARRETT M JAMES | Director | Nov 16, 2015 | Option Exercise | $0.33 | 9,445 | 3,117 | 4,491,203 | Nov 18, 2015, 02:19 PM |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | Nov 16, 2015 | Sale | $6.91 | 452 | 3,123 | 4,490,751 | Nov 18, 2015, 02:18 PM |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | Nov 16, 2015 | Option Exercise | $0.33 | 9,445 | 3,117 | 4,491,203 | Nov 18, 2015, 02:18 PM |
| Hahn Brian M. | CFO | Feb 27, 2015 | Option Exercise | $1.12 | 5,000 | 5,600 | 14,085 | Mar 03, 2015, 04:08 PM |
| King Rachel K. | President, CEO | Feb 24, 2015 | Option Exercise | $1.12 | 50,000 | 56,000 | 167,206 | Feb 26, 2015, 05:02 PM |
| HENOS MICHAEL A | Director | Dec 22, 2014 | Sale | $8.44 | 10,659 | 89,913 | 469,454 | Dec 23, 2014, 04:30 PM |
| HENOS MICHAEL A | Director | Dec 19, 2014 | Sale | $8.61 | 10,598 | 91,277 | 480,113 | Dec 23, 2014, 04:30 PM |
| HENOS MICHAEL A | Director | Dec 15, 2014 | Sale | $8.98 | 1,604 | 14,404 | 495,832 | Dec 17, 2014, 06:10 PM |
| HENOS MICHAEL A | Director | Dec 17, 2014 | Sale | $8.97 | 5,121 | 45,935 | 490,711 | Dec 17, 2014, 06:10 PM |
| HENOS MICHAEL A | Director | Dec 15, 2014 | Option Exercise | $0.33 | 43,628 | 14,397 | 497,436 | Dec 17, 2014, 06:10 PM |
| King Rachel K. | President, CEO | Jun 18, 2014 | Option Exercise | $1.12 | 100,000 | 112,000 | 108,706 | Jun 20, 2014, 04:00 PM |
| HENOS MICHAEL A | Director | Jun 13, 2014 | Buy | $6.21 | 5,000 | 31,050 | 12,562 | Jun 13, 2014, 04:01 PM |
| HENOS MICHAEL A | Director | Jun 12, 2014 | Buy | $6.54 | 6,000 | 39,240 | 7,562 | Jun 13, 2014, 04:01 PM |
| HENOS MICHAEL A | Director | Apr 03, 2014 | Option Exercise | $1.12 | 1,562 | 1,749 | 1,562 | Apr 03, 2014, 04:38 PM |
| BARRIS PETER J | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 487,500 | 3,900,000 | 4,481,758 | Jan 15, 2014, 05:16 PM |
| BARRIS PETER J | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 512,500 | 4,100,000 | 4,093,377 | Jan 15, 2014, 05:16 PM |
| SANDELL SCOTT D | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 512,500 | 4,100,000 | 4,093,377 | Jan 15, 2014, 05:15 PM |
| SANDELL SCOTT D | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 487,500 | 3,900,000 | 4,481,758 | Jan 15, 2014, 05:15 PM |
| BARRETT M JAMES | Director | Jan 15, 2014 | Buy | $8.00 | 512,500 | 4,100,000 | 4,093,377 | Jan 15, 2014, 05:15 PM |
| BARRETT M JAMES | Director | Jan 15, 2014 | Buy | $8.00 | 487,500 | 3,900,000 | 4,481,758 | Jan 15, 2014, 05:15 PM |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 512,500 | 4,100,000 | 4,093,377 | Jan 15, 2014, 05:14 PM |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | Jan 15, 2014 | Buy | $8.00 | 487,500 | 3,900,000 | 4,481,758 | Jan 15, 2014, 05:13 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
FUNDS WITH A POSITION IN GLYCOMIMETICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 758,696 | 0.00007% | -0.94% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 257,000 | 0.00107% | -51.17% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 405,335 | 0.00017% | 13.1% | Other |
| D. E. SHAW & CO., INC. | 36,630 | 0.00002% | Exited | Other |
CHANGE IN SHARES OUTSTANDING FOR GLYCOMIMETICS INC
STOCK BUYBACKS FOR GLYCOMIMETICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 09/30/2022
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
06/30/2022
0.03%
1Q
03/31/2022
0.11%
2Q
12/31/2021
1.82%
3Q
09/30/2021
2.19%
4Q
06/30/2021
2.48%
5Q
03/31/2021
3.33%
6Q
12/31/2020
14.58%
7Q
09/30/2020
16.51%
8Q
06/30/2020
19.91%
9Q
03/31/2020
20.22%
10Q
12/31/2019
21.11%
11Q
09/30/2019
21.23%
12Q
06/30/2019
21.34%
13Q
03/31/2019
21.36%
14Q
12/31/2018
27.64%
15Q
09/30/2018
29.85%
16Q
Load More